Search Results

Public Health At its core, Catherine Demery’s research  is about receptors and signaling pathways—how mu-opioid And because naloxone cannot reverse xylazine, the interventions that once worked for opioid overdoses And because naloxone only targets opioids, it cannot reverse xylazine. By displacing opioids from the mu-opioid receptor, it restores breathing within minutes. First responders describe revivals that don’t feel like revivals, as if the body is still trapped in a pharmacological

There, she chose to write a review on genetic variation in susceptibility to alcoholism and opioid addiction—a Returning to the Opioid Questions That Mattered Now, as a PhD candidate in the Traynor and Anand labs at the University of Michigan, Catherine is focused on the mechanisms of opioid-induced respiratory It’s rigorous pharmacology, but deeply tied to urgent public health needs. "I've always been really passionate and somewhat sensitive to people who struggle with opioid abuse.

While writing a literature review on opioid and alcohol addiction susceptibility, something shifted. Rather than treating opioid pharmacology as a purely theoretical exercise, she collaborates with harm-reduction This approach makes her models not just rigorous, but translational—bridging the gap between receptor pharmacology That personal loss transforms complex receptor pharmacology into something immediate and human. And GPCR pharmacology isn’t just an academic pursuit—it’s essential to understanding and responding to

How GPCR pharmacology connects molecular insights to real-world interventions. how fentanyl and xylazine shut down breathing through different mechanisms—work that blends receptor pharmacology now and see how one scientist is turning molecules into a mission, bridging the gap between receptor pharmacology GPCR ecosystem , GPCR training program , GPCR podcast , opioid pharmacology , xylazine research , mu opioid receptor , pharmacogenomics , fentanyl epidemic , preclinical pharmacology Enjoying the Dr.

Ajay Yekkirala is a GPCR pharmacologist, biotech entrepreneur, and co-founder of Superluminal Medicines strategic leaders seeking new drug development models Anyone curious about where AI meets molecular pharmacology /PhD, a rejection letter pivoted him into a PhD program at the University of Iowa, where he studied opioid pharmacology under the legendary Dr. Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

Committee Sponsors GPCR Retreat Program < Back to schedule Regulation and role of mitochondria delta opioid Soon About Louis Gendron "Dr Louis Gendron, PhD is tenured Professor and Chair of the Department of Pharmacology-Physiology He has 20+ years of experience in in vitro and in vivo GPCR pharmacology and has published seminal papers where he used various approaches to describe the role of opioid receptors in pain and anagesia as well as to study the mechanisms involved in the cellular trafficking of the delta opioid receptor.